Peter Jones in reporting on the outcome of a recent meeting of haemophilia centre directors stated that although the product Haemofil was connected to the outbreak of hepatitis at the time, that it was clear all concentrates carried the risk.
Chronology Information
Date:
Chapter/issue
Pharmaceutical Companies
Key Person(s)
Dr Peter M Jones